Conselho Regional de Medicina do Estado de São Paulo. Cuidado paliativo. São Paulo: CREMESP, 2008. p. 370.

Ferreira MBC. Princípios no Tratamento de Dor. In: Fuchs FD, Wannmacher L. Farmacologia Clínica: Fundamentos da Terapêutica Racional, 4ª edição. Rio de Janeiro: Guanabara Koogan, 2010, p.214-30.

Rathmell JP, Fields HL. Dor: fisiopatologia e tratamento. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Medicina Interna de Harrison. 18ª ed. Rio de Janeiro: McGraw-Hill, Artmed, 2013, p. 93-101.

World Health Organization. Cancer pain relief: with a guide to opioid availability. Second edition. Geneva: WHO, 1996.

Tapentadol. Acute or chronic pain: no therapeutic advance. Prescrire Int 2014; 23(149): 121-4.

National Prescribing Service Limited - NPS MedicineWise. NPS RADAR. Tapentadol sustained release (Palexia SR) for chronic, severe disabling pain. Published data: 1 August 2014. [cited on 13 Oct 2014]. Available from: http://www.nps.org.au/__data/assets/pdf_file/0005/257162/Tapentadol.pdf.

British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 65 ed. London: BMJ Publishing Group, APS Publishing, 2013.

Truven Health Analytics: Martindale: The Complete Drug Reference. Thomson MICROMEDEX, Greenwood Village, Colorado, USA. [cited on 14 Oct 2014]. Available from: http://www.micromedexsolutions.com.

Mercier F, Claret L, Prins K, BrunoR. A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant PainPain Ther (2014) 3:31–44. DOI 10.1007/s40122-014-0023-5.

Riemsma R, Forbes C, Harker J, Worthy G, Kate Misso, Schäfer M, et al. Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 2011; 27: 1907-30.